Contact

Novo Nordisk is pleased to introduce Ozempic^® (semaglutide), a new once-weekly GLP-1 RA^* for the management of type 2 diabetes.^1,2

The dinner meeting will comprise expert presentations and discussions on where guidelines recommend the use of GLP-1 RAs in the treatment algorithm for type 2 diabetes and the early use of Ozempic^®. Speakers will share their clinical experience with Ozempic^®, practical approaches to optimising patient care and the quality use of this medicine.

^{*GLP-1 RA = glucagon-like peptide 1 receptor agonist.}

REGISTER FOR THE OZEMPIC^® LAUNCH ROADSHOW

Select your location below

ADELAIDE

Tuesday 1 September

Perth

Wednesday 2 September

BRISBANE

Date TBC

TOWNSVILLE

Date TBC

SYDNEY WEST

Date TBC

SYDNEY CBD

Date TBC

MELBOURNE

Virtual Event Date TBC

GEELONG

Virtual Event Date TBC

The Novo Nordisk Meeting Secretariat will work with venues and suppliers to ensure they have current COVID-19 safety procedures in place as per the state and federal recommendations, additional information is available here.

AGENDA

Time	Topic
6:15 PM	Arrival And Registration
6:30 PM	GLP-1 RA after metformin: A paradigm shift in T2DM management?
7:00 PM	Introducing Ozempic^®; Clinical Use and practical considerations
7:30 PM	Case Study: When Metformin is no longer enough - a practical case
8:00 PM	Q&A
8:30 PM	Meeting Close

speakers

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Dr Meg Henze

Originally from Geraldton, Meg completed her MBBS with Honours in 2009 from the University of Western Australia.

Dr Joey Kaye

Dr Kaye is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia.

Ozempic^® (semaglutide),
a new once-weekly GLP-1 RA* for the management
of type 2 diabetes.¹

^{*GLP-1 RA = glucagon-like peptide 1 receptor agonist.}

PBS Information: Authority Required (STREAMLINED). Type 2 diabetes.
Criteria Apply. Refer to PBS Schedule for full Authority Required Information.

Please click here to review full PI before prescribing. Further information is available on request from Novo Nordisk. GLP-1 RA = glucagon-like peptide 1 receptor agonist. Reference: 1. Ozempic^®(semaglutide) Approved Product Information. August 2019. Available at: https://www.novonordisk.com.au/healthcare-professionals.html. 2. Ozempic^® is a new once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of adults with insufficiently controlled type 2 diabetes. Full PI is available from http://www.novonordisk.com.au

Enquiries

For enquiries on your registration or more information about the roadshow please contact us at:

Novo Nordisk Meeting Secretariat

Privacy Policy | Terms of Service | Contact Us

Ozempic^® is a registered trademark of Novo Nordisk A/S. Novo Nordisk Pharmaceuticals Pty. Ltd.
Level 3, 21 Solent Circuit, Baulkham Hills NSW 2153. ABN 40 002 879 996. NovaCare^® Customer Care Centre (Australia) 1800 668 626. https://www.novonordisk.com.au
Date of preparation: August 2020. AU20OZM00152.

.